Baytril Flavour Tablets 150 mg

Land: Malaysia

Sprache: Englisch

Quelle: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Wirkstoff:

Enrofloxacin

Verfügbar ab:

ELANCO MALAYSIA SDN BHD

INN (Internationale Bezeichnung):

Enrofloxacin

Einheiten im Paket:

5 x 10 Tablets

Hergestellt von:

KVP Pharma + Veterinar Produkte GmbH

Fachinformation

75 mm
210 mm
148 mm
FRONT PAGE
Pharmacode
Read Direction
Template: PI_148x210mm_Kiel_v2a
• Item code placement is flexible
and can be moved to suit artwork
Page 1 / 2
502168APK
BAYTRIL FLAV 150 MG TAB
90208932
LF
LBAH
N/A
90202870
148 x 210 mm
N/A
TPM_016192
6 pt
ORT / HV / 06.05.2022
V1
Laetus: 0035
N/A
BLACK
Non-prining
TM
90208932
PRODUCT DESCRIPTION
Baytril Flavour Tablets 150 mg is a light brown
to brown, slightly marbled, round and planar
tablet. Each tablet contains 150 mg of enroflo-
xacin.
PHARMACODYNAMICS
Enrofloxacin is a member of the fluoroquinolone
class of chemical compounds. It has bacteri-
cidal activity which is mediated via a bond to
the A-subunit of bacterial DNA gyrase and the
resulting selective inhibition of this enzyme.
DNA gyrase is a topoisomerase, a group of
enzymes that are involved in the replication,
transcription and recombination of DNA in
bacteria. Fluoroquinolones also influence
bacteria in the resting phase by altering cell
wall permeability. These mechanisms explain
why the viability of bacteria declines rapidly
under the influence of enrofloxacin. The inhibi-
tory and bactericidal concentrations of enroflo-
xacin are close together. They are either
identical or only one or two dilution steps apart.
Enrofloxacin is effective against most gram-
negative bacteria, many gram-positive bacteria
and mycoplasmas at low concentrations.
PHARMACOKINETICS
Administration of enrofloxacin leads to compa-
rable serum levels after both oral (Baytril
tablets) and subcutaneous administration. Peak
serum concentrations of the active ingredient
in serum and tissue are reached within one to
two hours after administration (oral or subcut-
aneous) of 5 mg/kg body weight. Enrofloxacin
has a high distribution volume. Concentrations
in tissues and organs are usually significantly
higher than serum concentrations. The minimum
inhibitory concentration of the relevant patho-
gens is therefore very well covered by the
antibiotic activity in the serum and target
tissues. High concentrations may be expected